Top 3 Risk-Averse Stocks to Add Stability to Your Portfolio
While some investors relish the thrill of high-growth ventures with the potential for significant returns, others prioritize capital preservation and seek out investments that offer security and st...
Chicago Court Upholds $45 Million Mesothelioma Verdict Against Johnson & Johnson
CHICAGO--(BUSINESS WIRE)--A Circuit Court in Cook County, Ill., has denied a request by Johnson & Johnson (NYSE:JNJ) for a new trial in a mesothelioma lawsuit decided in April, upholding a jury ver...
Why Johnson & Johnson (JNJ) Dipped More Than Broader Market Today
Johnson & Johnson (JNJ) concluded the recent trading session at $160.50, signifying a -0.42% move from its prior day's close.
J&J to invest more than $2 billion in new manufacturing facility
Johnson & Johnson said on Tuesday it will invest more than $2 billion to build a new manufacturing facility at Wilson, North Carolina.
AHF: J&J Retreats From Its Scheme to Gut 340B Drug Pricing Program
WASHINGTON--(BUSINESS WIRE)--AHF: J&J Retreats from its Scheme to Gut 340B Drug Pricing Program.
AHF Hails HRSA Stance on J&J's Illegal Attack on 340B Program
WASHINGTON--(BUSINESS WIRE)--AHF Hails HRSA Stance on J&J's Illegal Attack on 340B Program.
J&J Seeks 3rd Talc-Related Bankruptcy: Time to Sell the Stock?
We suggest a new investor should avoid buying JNJ's stock now due to uncertainty surrounding its legal battles.
J&J subsidiary files for bankruptcy for third time to settle talc lawsuits
Under the proposal, Johnson & Johnson will pay $8B to claimants over 25 years.
Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and F...
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”) announced that its subsidiary, Red River Talc LLC (“Red River”), filed a voluntary prepackaged Chapter 11 bankrup...
J&J subsidiary files for bankruptcy to advance $8 billion talc settlement
A Johnson & Johnson subsidiary filed for bankruptcy for a third time on Friday as the healthcare giant seeks to advance an approximately $8 billion proposed settlement that would end tens of thousa...
J&J's Rybrevant Receives FDA Nod for Expanded Use in NSCLC
With this approval, JNJ's Rybrevant is now approved for a total of four indications in the United States.
Johnson & Johnson Commemorates 50 Years in Singapore with a Series of Events Marking a Remarkable Milestone
SINGAPORE, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Johnson & Johnson (J&J), a leading healthcare company, announced its 50th anniversary in Singapore. Guided by Our Credo to put the needs and well-being...
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
Johnson & Johnson (JNJ) closed the most recent trading day at $166.99, moving +0.89% from the previous trading session.
Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-inv...
TAR-200 plus cetrelimab effective in reducing tumor size in those with muscle-invasive disease, potentially improving surgical outcomes and lowering risk of recurrence BARCELONA, Spain , Sept. 16, ...
New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus Calmette-Guérin (BCG)-unresponsive BAR...
Related Companies